Skip to main content

01.03.2012 | Original Article | Ausgabe 3/2012

Supportive Care in Cancer 3/2012

The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA

Supportive Care in Cancer > Ausgabe 3/2012
Sherry L. Wolf, Debra L. Barton, Rui Qin, Edward J. Wos, Jeff A. Sloan, Heshan Liu, Neil K. Aaronson, Daniel V. Satele, Bassam I. Mattar, Nathan B. Green, Charles L. Loprinzi
Wichtige Hinweise
Additional participating institutions include: Cedar Rapids Oncology Program CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld, MD); Geisinger Clinic & Medical Center CCOP, Danville, PA 17822 (Albert M. Bernath, Jr., M.D.); Rapid City Regional Hospital, Inc, Rapid City, SD 57701 (Richard C, Tenglin, M.D.); Sioux Community Cancer Consortium, Sioux Falls, SD 57105 (Loren K. Tschetter, M.D.); Toledo Community Hospital Oncology Program (Rex Mowat, M.D.); Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN 55416 (Patrick J. Flynn, M.D.); Mayo Clinic Arizona, Scottsdale, AZ 85259-5404 (Tom R. Fitch, M.D.); Hematology/Oncology Centers of the Northern Rockies, Billings, MT 59101 (Benjamin Marchello, M.D.); Carle Cancer Center, Urbana, IL 61801 (Kendrith M. Rowland, Jr, M.D.); Spartanburg Regional Medical Center, Spartanburg, SC 29303 (James D. Bearden, III, M.D.); Columbia River Oncology Program, Portland, OR 97225 (Janet C. Ruzich, M.D.); and Illinois Oncology Research Assn. CCOP, Peoria, IL 61615–7828 (John W. Kugler, M.D.).



Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20).


Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items.


A majority of the 199 patients accrued to this study reported “quite a bit” to “very much” numbness (57%) or tingling (63%) in the hands compared to “a little” or “not at all” (numbness (43%), tingling (38%)). Fewer patients reported “quite a bit” to “very much” shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities.


In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

Supportive Care in Cancer 3/2012 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.